H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the FDA approved Vykat for treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome. The firm says the list price of $466,200 annually is above its original assumption.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
- Soleno Therapeutics price target raised to $108 from $74 at Stifel
- Soleno Therapeutics price target raised to $81 from $70 at Guggenheim
- Soleno Therapeutics price target raised to $102 from $72 at Baird
- Soleno Therapeutics price target raised to $105 from $75 at Laidlaw